ATS 2020 Advance Program

therapeutics. Presentations from experts in the field will be complemented by abstract presentations related to the topic being discussed. Chairing: E.R. Neptune, MD, Baltimore, MD J.M. D’Armiento, MD, PhD, New York, NY 2:15 Introduction to Scientific Breakthroughs Session E.R. Neptune, MD, Baltimore, MD 2:17 Self-Renewing Alveolar Epithelial Cells Derived from Patient-Specific iPSCs D.N. Kotton, MD, Boston, MA 2:38 Lung Neuroendocrine Networks Revisited X. Sun, PhD, San Diego, CA 2:59 Lung Progenitors in Epithelial Renewal Following Injury H.A. Chapman, MD, San Francisco, CA 3:20 Tissue Scaffolds Reveal Instructive Macrophage Subsets J. Elisseeff, PhD, Baltimore, MD 3:41 Introduction of Keynote Speaker C. Kim, PhD, Boston, MA 3:45 Modeling Airway Diseases in Human Organoids H. Clevers, MD, PhD, Utrecht, Netherlands BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM C86 ATS MYTHBUSTERS: NOVEL SINGLE CELL PROFILING TECHNOLOGIES WILL HAVE A SIGNIFICANT IMPACT ON THE UNDERSTANDING AND MANAGEMENT OF PULMONARY FIBROSIS Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Structure and Function; Section on Genetics and Genomics 2:15 p.m. - 4:15 p.m. Target Audience This unique format fits every person interested in new research about pulmonary fibrosis, biomarkers, drug discovery and Precision Medicine. All trainees at all levels, clinicians, basic and translational researchers, and patient advocacy group members wi Objectives At the conclusion of this session, the participant will be able to: • understand what are single cell technologies and how they can be used to better understand idiopathic pulmonary fibrosis and other lung diseases; • know how insights derived from single cell technologies allow discovery of disease endotypes and development of precision medicine approaches in IPF and other interstitial lung disease; • grasp the extent of cellular aberrations in epithelial, mesenchymal, immune and vascular cells that characterize the lungs of patients with IPF and other ILD. In this provocative and interactive session we will explore using the “mythbusters” format the hypothesis that new insights derived from single cell profiling technologies will transform the understanding, diagnosis and management of pulmonary fibrosis. Followed by talks by leading researchers, the mythbusters will discuss the validity of the hypothesis. The session will end with a vote by the audience. Active audience participation will be encouraged throughout a live tweeting stream. Chairing: X. Yan, PhD, New Haven, CT N. Banovich, PhD, Phoenix, AZ R. Zemans, MD, Ann Arbor, MI 2:15 A Patient’s Perspective Speaker To Be Announced 2:20 Rules of the MythBuster Session R. Zemans, MD, Ann Arbor, MI 2:23 Introduction of the Myth N. Banovich, PhD, Phoenix, AZ 2:26 What Do We Mean When We Say “Single Cell Analysis” of Pulmonary Fibrosis? A. Misharin, MD, PhD, Chicago, IL ATS 2020 • Philadelphia, PA TUESDAY • MAY 19 117